Abstract:Human natural killer (NK) cells can target tumor cells in an antigen-specific manner by the recognition of cell bound antibodies. This process induces antibody-dependent cell-mediated cytotoxicity (ADCC) and is exclusively mediated by the low affinity IgG Fc receptor CD16A (FcγRIIIA). Exploiting ADCC by NK cells is a major area of emphasis for advancing cancer immunotherapies. CD64 (FcγRI) is the only high affinity IgG FcR and it binds to the same IgG isotypes as CD16A, but it is not expressed by human NK cells. We have generated engineered human NK cells expressing recombinant CD64 with the goal of increasing their ADCC potency. Preclinical testing of this approach is essential for establishing efficacy and safety of the engineered NK cells. The dog provides particular advantages as a model, which includes spontaneous development of cancer in the setting of an intact and outbred immune system. To advance this immunotherapy model, we cloned canine CD16A and CD64 and generated specific mAbs. We report here for the first time the expression patterns of these FcγRs on dog peripheral blood leukocytes. CD64 was expressed by neutrophils and monocytes, but not lymphocytes, while canine CD16A was expressed at high levels by a subset of monocytes and lymphocytes. These expression patterns are similar to that of human leukocytes. Based on phenotypic characteristics, the CD16A+ lymphocytes consisted of T cells (CD3+ CD8+ CD5dim α/β TCR+) and NK cells (CD3- CD5- CD94+), but not B cells. Interestingly, the majority of canine CD16A+ lymphocytes were from the T cell population. Like human CD16A, canine CD16A was downregulated by a disintegrin and metalloproteinase 17 (ADAM17) upon leukocyte activation, revealing a conserved means of regulation. We also directly demonstrate that both canine CD16A and CD64 can induce ADCC when expressed in the NK cell line NK-92. These findings pave the way to engineering canine NK cells or T cells with high affinity recombinant canine CD64 to maximize ADCC and to test their safety and efficacy to benefit both humans and dogs.

The anti-canine distemper virus activities of ex vivo-expanded canine natural killer cells

Oncolytic activity of canine distemper virus in canine mammary tubular adenocarcinoma cells.

Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease

Antiviral efficacy of favipiravir against canine distemper virus infection in vitro

Isolation and characterization of canine natural killer cells

Antiviral activity of canine interferon lambda 3 expressed using a recombinant adenovirus against canine coronavirus, canine parvovirus, and canine distemper virus

Viral Pathogenesis, Recombinant Vaccines, and Oncolytic Virotherapy: Applications of the Canine Distemper Virus Reverse Genetics System

Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells

Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application

Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody

Transcriptome analysis of Vero cells infected with attenuated vaccine strain CDV-QN-1

Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells

Construction of a mavs-inactivated MDCK cell line for facilitating the propagation of canine distemper virus (CDV).

A Recombinant Canine Distemper Virus Expressing Interleukin-7 Enhances Humoral Immunity

Protective Immunity Against Canine Distemper Virus In Dogs Induced By Intranasal Immunization With A Recombinant Probiotic Expressing The Viral H Protein

Isolation and Phylogenetic Analysis of the Canine Distemper Virus from a Naturally Infected Dog in China

The recombinant EHV-1 vector producing CDV hemagglutinin as potential vaccine against canine distemper

Canine Distemper Virus Alters Defense Responses in an Ex Vivo Model of Pulmonary Infection

Canine Distemper Virus (Cdv)-Neutralizing Activities of an Anti-Cdv Canine-Derived Single-Chain Variable Antibody Fragment 4-15 (scfv 4-15) Screened by Phage Display Technology.

Quantitative Analysis of Cellular Proteome Alterations in CDV-Infected Mink Lung Epithelial Cells.